flanders.bio provides you with insights in the vibrant life sciences sector

Facts & Figures

CONSULT OUR LIFE SCIENCE DATABASE

 

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

 

Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.

 

Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.

 

The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.

 

Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.

News from flanders.bio and its members

Mithra Submits Myring™ for European Marketing Approval

Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, announces that it has filed Myring™ for marketing approval in Europe. Myring™ is Mithra’s version of Nuvaring™, a combined hormonal contraceptive vaginal ring made of ethylene vinyl acetate copolymers (EVA). The global market for Nuvaring™ amounts to approximately USD 960 million, with over 75% of sales in the US.

Entrepreneurship | 17 July 17
Read more
17
Jul
2017

Ablynx proposes appointment of Mrs. Hilde Windels as a new independent director

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that Hilde Windels will be nominated as an Independent Non-Executive Director at the Company's forthcoming Special General Meeting of its shareholders to be held on 18 August 2017

12
Jul
2017

Delphi Genetics receives GMP accreditation for plasmid DNA bioproduction

Delphi Genetics, a company specialized in genetic engineering, is very pleased to announce that it has just received the certificate of Good Manufacturing Practice (GMP) for plasmid DNA production. The GMP productions will be realized in clean rooms located in Delphi Genetics’ own facilities.

12
Jul
2017

Biocartis Group NV: Biocartis' Idylla(TM) Instrument and Idylla(TM) Console exempt from US FDA 510(k) notification requirements

Biocartis Group NV ('Biocartis' or the 'Company'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that on 11 July 2017 the US FDA[1] published a final list of devices that it has exempted from 510(k) premarket notification requirements in accordance with the US 21st Century Cures Act (signed into US law 13 December 2016). The product code applicable to the Biocartis Idylla(TM) Instrument and Idylla(TM) Console is included on this list. Consequently, Biocartis' Idylla(TM) Instrument and Idylla(TM) Console are no longer subject to 510(k) notification requirements prior to being placed on the US market for in vitro diagnostic use with FDA approved or cleared assays. All other US 510(k) requirements, including current Good Manufacturing Practices (cGMP) and vigilance reporting, remain in effect. With this exemption in place, Biocartis is complying with the instructions in the publication and can now withdraw the pending 510(k) submission for the Idylla(TM) Instrument and Idylla(TM) Console.

10
Jul
2017

BioInvent and ThromboGenics Amending Long-Standing Monoclonal Antibody Development Agreement

BioInvent International AB ("BioInvent") (OMXS: BINV) and ThromboGenics NV (Euronext Brussels: THR) today announce that they have agreed to amend their long-standing agreement, which covers the co-development of the novel anti-PlGF monoclonal antibody products TB-403 and THR-317. The revisions to the existing agreement have been aligned with each company's strategic ambitions and therapeutic focus.

17
Jul
2017

Ablynx proposes appointment of Mrs. Hilde Windels as a new independent director

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that Hilde Windels will be nominated as an Independent Non-Executive Director at the Company's forthcoming Special General Meeting of its shareholders to be held on 18 August 2017

12
Jul
2017

Delphi Genetics receives GMP accreditation for plasmid DNA bioproduction

Delphi Genetics, a company specialized in genetic engineering, is very pleased to announce that it has just received the certificate of Good Manufacturing Practice (GMP) for plasmid DNA production. The GMP productions will be realized in clean rooms located in Delphi Genetics’ own facilities.

12
Jul
2017

Biocartis Group NV: Biocartis' Idylla(TM) Instrument and Idylla(TM) Console exempt from US FDA 510(k) notification requirements

Biocartis Group NV ('Biocartis' or the 'Company'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that on 11 July 2017 the US FDA[1] published a final list of devices that it has exempted from 510(k) premarket notification requirements in accordance with the US 21st Century Cures Act (signed into US law 13 December 2016). The product code applicable to the Biocartis Idylla(TM) Instrument and Idylla(TM) Console is included on this list. Consequently, Biocartis' Idylla(TM) Instrument and Idylla(TM) Console are no longer subject to 510(k) notification requirements prior to being placed on the US market for in vitro diagnostic use with FDA approved or cleared assays. All other US 510(k) requirements, including current Good Manufacturing Practices (cGMP) and vigilance reporting, remain in effect. With this exemption in place, Biocartis is complying with the instructions in the publication and can now withdraw the pending 510(k) submission for the Idylla(TM) Instrument and Idylla(TM) Console.

10
Jul
2017

BioInvent and ThromboGenics Amending Long-Standing Monoclonal Antibody Development Agreement

BioInvent International AB ("BioInvent") (OMXS: BINV) and ThromboGenics NV (Euronext Brussels: THR) today announce that they have agreed to amend their long-standing agreement, which covers the co-development of the novel anti-PlGF monoclonal antibody products TB-403 and THR-317. The revisions to the existing agreement have been aligned with each company's strategic ambitions and therapeutic focus.

Z Life Sciences

A look behind the scenes of the vibrant life sciences sector in Flanders, Belgium in 11 episodes.

1

VIB

VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.

2

imec

imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.

3

Bio Base Europe Pilot Plant

Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes. 

 

E-letter archive

UNDER CONSTRUCTION: here you will be able to consult the archive of our quarterly e-letter.

Interested in a regular update of the Life Sciences and biotech sector in Flanders?